Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ARTL
Artelo Biosciences, Inc. Common Stock
stock NASDAQ

At Close
Jul 20, 2026 3:41:00 PM EDT
1.12USD-2.609%(-0.03)68,251
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 20, 2026 9:07:30 AM EDT
1.14USD-0.870%(-0.01)582
After-hours
Jul 20, 2026 4:05:30 PM EDT
1.13USD+0.759%(+0.01)250
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 12, 2022
08:36AM EST  Artelo Biosciences Q1 EPS $(0.08) Up From $(0.14) YoY   Benzinga
08:30AM EST  Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022   GlobeNewswire Inc
Jan 11, 2022
08:34AM EST  Artelo Anticipates Accelerated Clinical Development For ART27.13 Following Its Classification Change In The United Kingdom   Benzinga
08:30AM EST  Artelo Anticipates Accelerated Clinical Development for ART27.13   GlobeNewswire Inc
Jan 10, 2022
09:00AM EST  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be participating at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.   GlobeNewswire Inc
Nov 29, 2021
08:36AM EST  Artelo Biosciences FY21 Operating Expenses $7.44M Vs $4.685M YoY   Benzinga
08:30AM EST  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the fiscal year ended August 31, 2021 and provided a business update.   GlobeNewswire Inc
Nov 1, 2021
06:30AM EDT  HC Wainwright & Co. Initiates Coverage On Artelo Biosciences with Buy Rating, Announces Price Target of $4   Benzinga
Sep 23, 2021
08:44AM EDT  New Study Comparing Plant-Derived and Synthetic CBD Efficacy Opens Door to Exciting Medical Uses of Cannabidiol   Benzinga
Sep 8, 2021
08:30AM EDT  Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual   GlobeNewswire Inc
Sep 7, 2021
12:38PM EDT  EXCLUSIVE: Artelo Biosciences CEO, Greg Gorgas Now Interviewing On Benzinga's Power Hour Show   Benzinga
11:45AM EDT  EXCLUSIVE: Artelo Biosciences CEO, Greg Gorgas To Appear On Benzinga's Power Hour Show At 12:30 p.m. EDT   Benzinga
Aug 4, 2021
08:30AM EDT  Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD   GlobeNewswire Inc
Jul 21, 2021
08:30AM EDT  Ladenburg Thalmann to Host R&D Showcase Featuring Artelo   GlobeNewswire Inc
Jul 12, 2021
08:35AM EDT  Artelo Biosciences Q3 EPS $(0.10) Up From $(0.27) YoY   Benzinga
08:30AM EDT  Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end   GlobeNewswire Inc
Jul 7, 2021
08:30AM EDT  Artelo Biosciences, Inc.(NASDAQ:ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will be presenting and hosting 1x1 meetings during the Ladenburg Thalmann Healthcare Conference taking place virtually July 13-14, 2021.   GlobeNewswire Inc
Jun 24, 2021
08:43AM EDT  New Cannabinoid-Based Drug Candidates from Artelo Biosciences Show Promise as Cancer and Mental Health Treatments; Key Data Due Before Year End   Benzinga
Jun 22, 2021
08:14AM EDT  Artelo Biosciences Highlights 2 Poster Presentations At 31st Annual International Cannabinoid Research Society Symposium, Jun. 22, 23   Benzinga
08:00AM EDT  Dr. Andrew Yates to Present Poster on the Companys ART27.13 Cancer Appetite Recovery Study   GlobeNewswire Inc
Jun 2, 2021
08:30AM EDT  Artelo Biosciences, Inc.(NASDAQ:ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.   GlobeNewswire Inc
May 4, 2021
08:28AM EDT  Kintara Therapeutics Appoints Tamara Seymour To Board   RTTNews
08:02AM EDT  Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors   PR Newswire
Apr 13, 2021
08:50AM EDT  Artelo Biosciences Q2 EPS $(0.11) Up From $(0.40) YoY   Benzinga
08:30AM EDT  Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK   GlobeNewswire Inc
Apr 12, 2021
08:37AM EDT  Artelo Biosciences Says Doses First Patient In CAReS Study With ART27.13 For Treatment Of Cancer-Related Anorexia And Weight Loss   Benzinga
08:30AM EDT  Artelo Biosciences Doses First Patient in CAReS Study with   GlobeNewswire Inc
Mar 19, 2021
10:00AM EDT  Artelo Biosciences Reports Accepted Into Alderley Park Oncology Development Program For FABP5 Inhibitor Biomarker Development   Benzinga
10:00AM EDT  Detection of elevated FABP5 associated with additional tumor types suggeststhe target for ART26.12 may be more broadly relevant in cancer therapy   GlobeNewswire Inc
Mar 11, 2021
07:14AM EST  Artelo Biosciences, Inc. To Present At Q1 Virtual Investor Summit On March 23rd   Benzinga
07:10AM EST  via InvestorWire Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the Q1 Virtual Investor Summit.   GlobeNewswire Inc
Mar 9, 2021
08:30AM EST  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Companys board of directors.   GlobeNewswire Inc
Mar 2, 2021
08:30AM EST  Artelo Biosciences to Present at the H.C. Wainwright Global Life   GlobeNewswire Inc
Feb 17, 2021
08:38AM EST  Artelo Biosciences Highlights Pre-Clinical Data Associated With Proprietary CBD Cocrystal Showing 'potential pharmacodynamic interactions of co-administration of cannabidiol (CBD) and tetramethylpyrazine (TMP) in cell-based models of cancer.'   Benzinga
08:30AM EST  Artelo Biosciences Announces Positive Pre-Clinical Data Associated   GlobeNewswire Inc
Feb 16, 2021
12:46PM EST  43 Stocks Moving In Tuesday's Mid-Day Session   Benzinga
08:30AM EST  Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as   GlobeNewswire Inc
Feb 12, 2021
02:17PM EST  Mid-Afternoon Market Update: Crude Oil Rises Over 2%; HubSpot Shares Spike   Benzinga
01:52PM EST  Mid-Day Market Update: Crude Oil Rises 2.5%; Energy Shares Spike   Benzinga
10:59AM EST  Mid-Morning Market Update: US Stock Futures Trend Down; Nasdaq Composite Dips 0.2%   Benzinga
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021   Benzinga
07:15AM EST  Ladenburg Thalmann Initiates Coverage On Artelo Biosciences with Buy Rating, Announces Price Target of $7   Benzinga
Feb 8, 2021
08:30AM EST  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its October 2020 financing. Existing investors agreed to exercise warrants for net proceeds of approximately $3 million.   GlobeNewswire Inc
Feb 3, 2021
08:10AM EST  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Feb. 3, 2021: FDX, TER, APHA, TAST, ARTL   Benzinga
Feb 2, 2021
08:36AM EST  Artelo Biosciences Announces Research Collaboration With Trinity College Dublin To Investigate ART27.13 For Treatment Of Cancer Cachexia   Benzinga
08:30AM EST  Artelo Biosciences, Inc.(NASDAQ:ARTL) today embarks on a collaboration with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia, a wasting syndrome that affects up to 80% of all cancer patients and is believed to hasten death in this population.   GlobeNewswire Inc
Jan 29, 2021
04:05PM EST  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the LSX World Congress to be held virtually between February 1-5, 2021.   GlobeNewswire Inc
Jan 14, 2021
12:23PM EST  Artelo Biosciences shares were trading higher after the company reported better-than-expected Q1 EPS results.   Benzinga
08:34AM EST  Artelo Biosciences Q1 EPS $(0.14) Beats $(0.38) Estimate   Benzinga
08:30AM EST  Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK   GlobeNewswire Inc
Jan 7, 2021
11:02AM EST  Maxim Group Upgrades Artelo Biosciences to Buy   Benzinga
Jan 5, 2021
08:30AM EST  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.   GlobeNewswire Inc
Dec 9, 2020
08:34AM EST  Artelo Biosciences Reports Filing Of Patent Application For New Formulation Of ART27.13   Benzinga
08:31AM EST  Artelo Biosciences Files Patent Application For New Formulation Of ART27.13   Benzinga
08:30AM EST  Artelo Biosciences Files Patent Application for New Formulation of   GlobeNewswire Inc
Dec 8, 2020
08:30AM EST  Artelo Biosciences to Present at The 13th Annual LD Micro Main   GlobeNewswire Inc
Dec 2, 2020
08:30AM EST  Artelo Biosciences, Inc.(NASDAQ:ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, todayannounced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Companys Board of Directors, effective November 30, 2020.   GlobeNewswire Inc
Nov 23, 2020
08:30AM EST  Artelo Biosciences and University of Western Ontario Awarded   GlobeNewswire Inc
Nov 20, 2020
04:21PM EST  Artelo Biosciences Announces That On Nov 17, The Co. Received A Written Notice From Nasdaq Indicating That The Co. Is Not In Compliance With Certain Listing Rule   Benzinga
Nov 19, 2020
05:45PM EST  U.K. Authorizes Artelo To Test Cancer Appetite Recovery Study Using Synthetic Cannabinoid   Benzinga
Nov 16, 2020
08:39AM EST  Artelo Biosciences Announces Clinical Trial Authorization To Commence Cancer Appetite Recovery Study For The Treatment Of Cancer-Related Anorexia, Weight Loss   Benzinga
08:30AM EST  Artelo Biosciences Announces Clinical Trial Authorization to   GlobeNewswire Inc
Nov 4, 2020
08:05AM EST  Artelo Biosciences FY20 EPS $(1.26), Down From $(1.00) YoY   Benzinga
08:00AM EST  -- Closed $7.6 Million Underwritten Public Offering -- Received Ethics Approval to Commence CAReS Study of ART27.13 in the UK -- Expanded Exclusive Worldwide License with Stony Brook University for Fatty Acid Binding Protein 5 (FABP5)inhibitor Platform   GlobeNewswire Inc
Nov 3, 2020
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Nov 2, 2020
09:10AM EST  Stocks Trading Near 52-Week Lows Before Open On Monday, Nov. 2, 2020: CLSN, MRTN, UTSI, LXRX, TTNP, ORTX, ARTL, PEI, CBL   Benzinga
Oct 29, 2020
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
Oct 22, 2020
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
Oct 21, 2020
08:36AM EDT  Artelo Biosciences Files Patent On Use Of Fatty Acid Binding Protein 5 Inhibitors For Treating Psychological Disorders   RTTNews
08:30AM EDT  Artelo Biosciences Files Patent on Use of Fatty Acid Binding   GlobeNewswire Inc
Oct 15, 2020
10:57AM EDT  Artelo Biosciences 13G Filing From Empery Asset Mgmt. Shows 6.67% Stake In Co.   Benzinga
Oct 14, 2020
04:05PM EDT  Artelo Biosciences, Inc. Announces Closing of $7.6 Million   GlobeNewswire Inc
Oct 9, 2020
08:31AM EDT  Artelo Biosciences Announces Pricing Of $6.6M At $0.75/Share   Benzinga
08:30AM EDT  Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized   GlobeNewswire Inc
Sep 29, 2020
10:58AM EDT  Why Artelo Biosciences Is Trading Higher Today   Benzinga
08:07AM EDT  Artelo Biosciences Receives Ethics Approval To Commence Its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) Of ART27.13 For The Treatment Of Cancer-Related Anorexia   Benzinga
08:00AM EDT  Artelo Biosciences Receives Ethics Approval to Commence its Cancer   GlobeNewswire Inc
Sep 11, 2020
09:00AM EDT  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.   GlobeNewswire Inc
Sep 10, 2020
09:15AM EDT  Artelo Biosciences to Participate in Two Keynote Panels at 3rd   GlobeNewswire Inc
Jul 17, 2020
04:43PM EDT  The Week In Cannabis: Stocks On The Rise, Earnings, Big Cannabis Sales, Moves In Argentina   Benzinga
Jul 14, 2020
09:36AM EDT  Artelo Biosciences Reports Q3 EPS $(0.27) Down From $(0.17) Q3 2019   Benzinga
09:25AM EDT  Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system and related biological signaling pathways, today reported financial and operating results for the third quarter ended May 31, 2020 of its fiscal year ending August 31, 2020 and provided a business update.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC